NASDAQ: TVRDTvardi Therapeutics Inc Stock
$2.01-0.01 (-0.5%)
Updated Jul 6, 2026
TVRD Price
$2.01
Fair Value Price
$2.64
Market Cap
$18.86M
52 Week Low
$1.50
52 Week High
$43.65
P/E
-1.22x
P/B
1.3x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$15.44M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.78
Operating Cash Flow
-$25M
Beta
1
Next Earnings
Aug 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
TVRD Overview
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TVRD's potential to beat the market
- TVRD doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important TVRD news, forecast changes, insider trades & much more!
TVRD News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TVRD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TVRD ($2.01) is undervalued by 23.81% relative to our estimate of its Fair Value price of $2.64 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
TVRD ($2.01) is significantly undervalued by 23.81% relative to our estimate of its Fair Value price of $2.64 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
TVRD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TVRD due diligence checks available for Premium users.
Valuation
TVRD fair value
Fair Value of TVRD stock based on Discounted Cash Flow (DCF)
Price
$2.01
Fair Value
$2.64
Undervalued by
23.81%
TVRD ($2.01) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TVRD ($2.01) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TVRD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TVRD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.22x
Industry
18.36x
Market
6.94x
TVRD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.3x
Industry
5.58x
TVRD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TVRD's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.8M
Profit Margin
0%
TVRD's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$25.8M
Liabilities
$11.3M
Debt to equity
0.78
TVRD's short-term assets ($25.33M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TVRD's short-term assets ($25.33M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TVRD's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
TVRD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.9M
Investing
$5.0M
Financing
$0.0
TVRD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TVRD vs Biotech Stocks
Tvardi Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.